NOGEN System

About NOTA Labs

NOTA Labs is an early-stage biotech leveraging nitric oxide's broad therapeutic properties—antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic—through two core platform technologies: the NOGEN electrochemical system for high-volume gas delivery and the LANOR UV-LED system for compact, localized generation. The company's pipeline addresses significant unmet needs in hospital-acquired infections (catheter lock solutions), neonatal care (PPHN), cardiac surgery, and chronic respiratory diseases. Backed by NIH SBIR funding, NOTA is positioned to advance its pre-clinical programs toward clinical validation in high-value medical markets.

About NOTA Labs

NOTA Labs is an early-stage biotech leveraging nitric oxide's broad therapeutic properties—antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic—through two core platform technologies: the NOGEN electrochemical system for high-volume gas delivery and the LANOR UV-LED system for compact, localized generation. The company's pipeline addresses significant unmet needs in hospital-acquired infections (catheter lock solutions), neonatal care (PPHN), cardiac surgery, and chronic respiratory diseases. Backed by NIH SBIR funding, NOTA is positioned to advance its pre-clinical programs toward clinical validation in high-value medical markets.

About NOTA Labs

NOTA Labs is an early-stage biotech leveraging nitric oxide's broad therapeutic properties—antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic—through two core platform technologies: the NOGEN electrochemical system for high-volume gas delivery and the LANOR UV-LED system for compact, localized generation. The company's pipeline addresses significant unmet needs in hospital-acquired infections (catheter lock solutions), neonatal care (PPHN), cardiac surgery, and chronic respiratory diseases. Backed by NIH SBIR funding, NOTA is positioned to advance its pre-clinical programs toward clinical validation in high-value medical markets.

Therapeutic Areas